Literature DB >> 16391958

Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia.

J Theisen1, H J Stein, M Feith, W K H Kauer, H J Dittler, D Pirchi, J R Siewert.   

Abstract

BACKGROUND: Barrett's metaplasia is the predominant precursor for the development of esophageal adenocarcinoma. This precancerous lesion has become the focus of various surveillance programs aimed at detecting earlier and therefore potentially curable lesions. However, sampling error by missing invasive cancer lesions is a common problem. This study aimed to identify preferred locations within a segment of Barrett's mucosa for the development of esophageal adenocarcinoma.
METHODS: The study group consisted of 213 patients with histologically proven esophageal adenocarcinoma. Of those, there were 134 cases of early cancer and 79 cases of locally advanced lesions. These patients received neoadjuvant chemotherapy. The frequency of intestinal metaplasia and the location of the tumor occurrence within the segment of intestinal metaplasia were assessed.
RESULTS: Intestinal metaplasia was found in 83% of the early lesions and in 98% of the advanced tumors after neoadjuvant chemotherapy. In 82.2% of the cases, the tumor was located at the distal margin of the intestinal metaplasia in patients with early tumor manifestations. The remaining tumor mass after neoadjuvant therapy also was located predominantly at the distal margin of the segment of intestinal metaplasia (85% of the cases).
CONCLUSIONS: The results demonstrate that almost all adenocarcinomas of the esophagus are based on the development of a segment of intestinal metaplasia. The distal margin of Barrett's mucosa seems to be the most vulnerable location for the development of invasive cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16391958     DOI: 10.1007/s00464-005-0187-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  27 in total

Review 1.  Esophagectomy after induction chemoradiation.

Authors:  M M DeCamp; S J Swanson; M T Jaklitsch
Journal:  Chest       Date:  1999-12       Impact factor: 9.410

2.  Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus.

Authors:  P Sharma; A P Weston; M Topalovski; R Cherian; A Bhattacharyya; R E Sampliner
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Classification of adenocarcinoma of the oesophagogastric junction.

Authors:  J R Siewert; H J Stein
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

Review 4.  Endoscopic features of the columnar-lined esophagus.

Authors:  G N Tytgat
Journal:  Gastroenterol Clin North Am       Date:  1997-09       Impact factor: 3.806

5.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

6.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.

Authors:  J B O'Connor; G W Falk; J E Richter
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

7.  Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients.

Authors:  J Rüdiger Siewert; M Feith; M Werner; H J Stein
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

Review 8.  Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.

Authors:  S R DeMeester; T R DeMeester
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

9.  Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study.

Authors:  C E Macdonald; A C Wicks; R J Playford
Journal:  BMJ       Date:  2000-11-18

10.  Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients.

Authors:  J H Peters; G W Clark; A P Ireland; P Chandrasoma; T C Smyrk; T R DeMeester
Journal:  J Thorac Cardiovasc Surg       Date:  1994-11       Impact factor: 5.209

View more
  6 in total

Review 1.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

2.  Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease.

Authors:  Claudia Ringhofer; Johannes Lenglinger; Barbara Izay; Katharina Kolarik; Johannes Zacherl; Margit Eisler; Fritz Wrba; Parakrama T Chandrasoma; Enrico P Cosentini; Gerhard Prager; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 3.  Review on novel concepts of columnar lined esophagus.

Authors:  Johannes Lenglinger; Stephanie Fischer See; Lukas Beller; Enrico P Cosentini; Reza Asari; Fritz Wrba; Martin Riegler; Sebastian F Schoppmann
Journal:  Wien Klin Wochenschr       Date:  2013-09-06       Impact factor: 1.704

Review 4.  Barrett's oesophagus: an ideal model to study cancer genetics.

Authors:  Massimiliano di Pietro; Rebecca C Fitzgerald
Journal:  Hum Genet       Date:  2009-04-14       Impact factor: 4.132

5.  Spatial predisposition of dysplasia in Barrett's esophagus segments: a pooled analysis of the SURF and AIM dysplasia trials.

Authors:  Cary C Cotton; Lucas C Duits; W Asher Wolf; Anne F Peery; Evan S Dellon; Jacques J Bergman; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2015-09-08       Impact factor: 10.864

6.  Longitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies.

Authors:  Kara L Raphael; Sumant Inamdar; Matthew J McKinley; Nichol Martinez; Kimberly Cavaliere; Allon Kahn; Cadman L Leggett; Prasad Iyer; Kenneth K Wang; Arvind J Trindade
Journal:  Clin Transl Gastroenterol       Date:  2021-02-22       Impact factor: 4.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.